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Increased activity of a factor ("transferangiotensin") favoring
the binding of angiotensin II to arterial wall in hypertension. A
plasma protein component with an apparent mol wt of 700,000
increases angiotensin II binding by macromolecules in arterial
wall extracts. Its activity is increased in several types of hyper-
tension, most prominently in essential hypertension.
Augmentation de l'activité d'un facteur ("transferangioten-
sine") qui favorise Ia liaison de l'angiotensine-ll a Ia paroi
artérielle au cours de l'hypertension. Une protéine plasmatique,
de poids moléculaire apparent de l'ordre de 700,000, augmente
Ia liason de l'angiotensine-II a des macromolecules des extraits
de parois artérielles. Son activité est augmentée dans différents
types d'hypertensions, surtout dans l'hypertension essentielle.
The experimental findings of Mizukoshi and
Michaelakis [1] have shown the existence, in plasma
from patients with essential hypertension, of one or
more factors that potentiates the action of angiotensin
II and norepinephrine. The hypertensive effect of
angiotensin II or norepinephrine appeared to be
increased when plasma from patients with essential
hypertension was administered simultaneously to
bilaterally nephrectomized rats.
The effect of angiotensin II is probably mediated
via its interaction with specific binding sites ("re-
ceptors") that are located in the arterial wall and
other target cells [2]. Quantitative estimation of the
affinity and number of arterial wall receptors has been
difficult. One such attempt at quantification has used
immunological methods [3].
Several laboratories have reported the presence of
angiotensin-binding macromolecules in plasma [4—7].
Although there is no evidence to suggest that norepi-
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nephrine is also bound by these binders, and no direct
evidence of their biological significance, we have
nevertheless elected to examine the plasma of normal
and hypertensive humans for the presence of factors
which might affect angiotensin's interaction with
arteries. It is the purpose of this paper to describe
some of the characteristics of such a factor which
favors the binding of angiotensin II by arterial wall.
The activity of this plasma compound is apparently
increased in several forms of arterial hypertension,
but mainly in that which is said to be "essential" in
type. Since its action appears to occur through an
increased transfer of angiotensin II to the arterial
wall receptor, we propose that it should be named
"transferangiotensin" (TA).
Methods
General reagents and apparatus. Val-5-angiotensin
II, Asp'-/-amide was purchased from Ciba (Basel,
Switzerland). Angiotensin I and its antibody were
obtained from Schwarz/Mann (Orangeburg, NY).
Antialdosterone-y-lactone antibody was purchased
from Antibodies Allied (Davies, California). 'H-
aldosterone (Ia, 2a) with a specific activity of 35 Ci/
mmole and sodium iodide, 80 to 140 mCi/ml (1251) in
NaOH solution, were acquired from the Amersham
Radiochemical Center (England). Lysozyme, with an
activity of 15,000 u/mg; pronase, containing 70,000
PUK U/g; and activated charcoal were purchased
from Merck and Co. (Darmstadt, West Germany).
Dextran T-70, Sephadex G-25 and G-200 and
Sepharose 6-B were purchased from Pharmacia
(Sweden). Ion exchange paper chromatography sheets,
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type P87, were obtained from Whatman (England).
Cellulose acetate strips for electrophoresis were pur-
chased from Atom (Barcelona). Dowex-1 ion ex-
change resin, 200—400 mesh, was obtained from
Sigma (St. Louis, MO). Human albumin, y-globulin
(IgG) and fibrinogen were the gift of Laboratorios
Hubber (Barcelona). Anti-angiotensin II antibody was
developed according to the procedure of Goodfriend,
Ball and Farley [8].
Spectrophotometric readings were performed on a
spectrophotometer (Hitachi-Perkin Elmer, type 139).
Centrifugation was performed in a refrigerated centri-
fuge (Sorvall RC-2B). Radioactivity was counted in a
liquid scintillation counter (Nuclear Chicago, Isocap-
300). Collections during chromatography were per-
formed with a fraction-cutter (Shandon-MBI), Elec-
trophoresis was carried out in an electrophoresis
apparatus (Atom-500).
Plasma samples. Plasma was obtained from normal
subjects and hypertensive patients by taking 20 ml of
peripheral venous blood in the presence of 0.05 ml of
20% sodium edetate (EDTA), pH 7.4. The samples
were chilled and centrifuged at 4°C for ten minutes at
6,000 rpm on a rotor (SE-2 Sorvall). The supernatants
were stored at —20°C, until assay.
Etiology of hypertension. Five clinical indexes were
used to describe the hypertensive patients: 1) history
and physical examination; 2) levels of plasma renin
activity, as described by the radioimmunoassay method
of Haber et al [9] and modified according to Pinto and
Arellano [10]; 3) urinary excretion of aldosterone
using the radioimmunoassay procedure of Farmer et al
[11]; 4) urinary excretion of 17-hydroxy [12] and 17-
ketosteroids [13]; and 5) urinary excretion of vanil-
lylmandelic acid [14]. These determinations were
performed while the patients were maintained on a
normal sodium diet and were receiving no drug
therapy.
lodination and purjflcation of angiotensin II. Angio-
tensin II was labeled by a modification of the method
of Hunter and Greenwood [15]. '251-sodium iodide,
5 mCi in 50 l of NaOH solution, pH 8 to 11, was
mixed with 20 1 of 0.3 M potassium phosphate
buffer (pH 7.5), 15 l of Chioroamine T (3.6 mg/mi in
0.3 M phosphate buffer, pH 7.5) and 4 g of angio-
tensin II. The mixture was incubated at room tem-
perature for 15 sec. The reaction was stopped with
75 ii of sodium metabisulfite (2.4 mg/ml), in 50 m
potassium phosphate buffer (pH 7.5). The solution
was acidified by adding 2 tl of 4 M acetic acid.
Purification of labeled angiotensin II was performed
on a 10 x 0.2 cm column (Dowex-1), equilibrated by
thorough washing with 10 mivi HCI. The sample was
eluted in 0.5 ml fractions with water. To each fraction,
20 I of 0.5 M sodium phosphate buffer (pH 7.5) and
0.2 casein were added. Radioactive samples were
pooled together and stored at —20°C until required.
The purification procedure was tested by spotting 10
cpm on ion exchange paper followed by descending
chromatography on the system pyridine-acetic acid-
water-ethanol (65:27:278 :400) and autoradiographed
according to the method of Goodfriend et al [8]. The
mass of radioactive peptide was determined by the
procedure of Jones [16]. Specific activity varied from
0.15 to 0.22 mCi/g.
Preparation of the arterial wall "receptor". Arterial
wall receptor was obtained from albino rabbits of
1.5 kg body wt, housed and fed under routine con-
ditions. After being fasted overnight, the animals were
killed by decapitation. The aorta was dissected from
the point of its origin in the heart to the iliac bifurca-
tion and washed free of blood in cold 0.9% sodium
chloride in 5 m sodium phosphate buffer (pH 7.4).
The aorta was suspended in 30 ml of the same buffer
and homogenized with a blender (Mini-Pimer) at
4°C, for three minutes; the suspension was then
homogenized further with a homogenizer (Afora,
Barcelona). The suspension was centrifuged at 30,000
x g for 30 mm. The supernatant was stored at —20°C
until needed. Before each assay, the arterial extract
was diluted with saline-phosphate buffer to a final
concentration of 5 mg/mi of protein, as determined by
the biuret method [17].
Individual experiments were performed with the
extract of aortas from different rabbits, and repeated
utilizing at least three different preparations.
Angiotensin binding assay systems. Angiotensin
binding was measured by three different systems: a)
capability of the plasma to affect angiotensin binding
by arterial wall, b) binding by arterial wall and c)
binding by plasma itself.
a. "Transferangiotensin" activity (potentiation of
arterial binding). The transferangiotensin assay sys-
tem involved the measurement of angiotensin bound
by the arterial wall when blood plasma was added.
Polystyrene tubes contained in a final volume of
1 ml: 10 moles of sodium phosphate buffer (pH 7.4),
50 to 60 ig of rabbit arterial wall extract, 10 g of
lysozyme, approximately 10,000 cpm of '251-angioten-
sin II and varying amounts of plasma (usually 2 to
50 I) from either normal or hypertensive patients. In
control tubes, either arterial wall extract, plasma, or
both, were omitted.
After incubation at 4°C for 24 hr, the separation of
free from bound angiotensin II was performed by
adding 1 ml of a suspension of 5% activated charcoal
and 0.5°/ Dextran in 5 m sodium phosphate buffer
(pH 7.4). After thorough mixing, the incubation
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mixtures were allowed to stand at 4°C for 15 mm, then
centrifuged for ten minutes at 6,000 rpm in a rotor
(Sorvall SE-2). Supernatants were counted in 15 ml of
scintillation fluid [18]. Radioactivity in the super-
natant after coated charcoal adsorption was taken as
the measure of angiotensin II bound to the macro-
molecules in either the arterial wall extract or plasma.
Charcoal concentration (between 5 and 0.32%) had
no significant effect on transferangiotensin activity.
Specificity of the plasma as a source for transferangio-
tensin was shown by replacing it with the same amount
of protein in a liver extract.
b. Transferangiotensin unit definition. A unit is
defined as the amount of plasma needed to increase by
1 the angiotensin bound by the arterial wall extract,
after blanking out the bound radioactivity by the
plasma and the arterial wall as separately assayed.
c. Binding by arterial wall. The assay system con-
tained the same ingredients already mentioned, but
plasma was left out. Increasing amounts of unlabeled
angiotensin II (from 0 to 200 ng) were added to the
assay system. Control tubes contained no arterial
extract.
d. Binding by plasma. This was assessed as already
described using an aliquot of plasma (50 t1). A curve
of displacement of labeled angiotensin II by unlabeled
angiotensin II was determined by adding increasing
amounts of unlabeled angiotensin to the tubes con-
taining plasma and a constant amount of labeled
angiotensin.
e. Physical-chemical properties of "transferangio-
tensin". These experiments were performed with a
pool of plasma from hypertensive patients. 1. Opti-
mum pH. The effect of the pH on the ability of plasma
to potentiate binding activity to arterial extract was
tested by replacing the phosphate buffer with 10
limoles of Tris-HCI buffer at different pH's from 5 to
9. The reaction was carried out as described. 2. Dialysis.
One ml of hypertensive plasma was dialyzed at 4°C in
cellophane tubing (Visking) against two changes (2
liters each) of 5 m sodium phosphate buffer (pH
7.4). The dialysate was evaporated to dryness at 35°C
in a flash evaporator (Büchi). The residue was dis-
solved in 0.5 ml of dialysis buffer. "Transferangio-
tensin" activity was assayed before and after dialysis
and in the dissolved dialysate. 3. Temperature. One ml
of hypertensive plasma was heated at 100°C for five
minutes and the precipitate was removed by centri-
fugation. 4. Extract with solvents. One ml of hyper-
tensive plasma was extracted with 10 ml of ether. The
ether layer was removed and evaporated to dryness
under nitrogen. The residue was dissolved in 1 ml of
5 m sodium phosphate buffer (pH 7.4) and the
"transferangiotensin" activity assayed. 5. Protein
digestion. One ml of hypertensive plasma was incu-
bated for 72 hr at 4°C in the presence of 100 g of
pronase, 10 moles of sodium borate buffer (pH 7.5)
and 0.5 moles of calcium chloride. The reaction was
terminated by adding 10 tmoles of sodium EDTA
(pH 7.4). In subsequent tests the same amount of
EDTA was added to control assay tubes. 6. Metal and
ion effects. To test the effects of metals in the assay
system, 10 moles of sodium EDTA (pH 7.4) were
added. Specific ion effects were tested by adding in-
creasing amounts of sodium chloride, potassium
chloride or calcium chloride, varying from 0 to 1
mole per assay tube.
f. Characterization of the potentiating factor. Charac-
terization of components involved in potentiating
angiotensin binding was performed by gel chromatog-
raphy and electrophoresis. 1. Fractionation of plasma
angiotensin binders. Columns of Sephadex G-25,
G-200 and Sepharose 6-B, 35 x 1.8 cm in size, were
thoroughly washed with 0.1 M sodium phosphate
buffer (pH 7.4). The samples were applied to the
columns with a Sephadex applicator. Elution was
performed at room temperature with the phosphate
buffer at a rate of 0.5 mI/mm. Radioactivity was
counted in each 1-mi fraction. The samples applied to
the columns contained in a final volume of I ml:
10 moles of phosphate buffer (pH 7.4), 10 g of
lysozyme, 2 x 106 cpm of 1251-angiotensin II, 0.2 ml of
either normal or pooled hypertensive plasma and 0.6
mg of protein from rabbit arterial wall. In six experi-
ments, pooled plasma was replaced by individual
plasma samples from subjects 4, 5 and 6 (controls) and
patients 7,8 and 9. Incubation mixtures without plasma
were also prepared, incubated at 4°C for 24 hr and then
applied to the column. Some control samples were
applied without prior incubation. For calculation of
mol wt, the columns were standardized utilizing
human albumin, y-globulin and fibrinogen. 2. Charac-
terization of "transferangiotensin" activity. Hyper-
tensive plasma samples of 15 ml were lyophilized, and
the residue dissolved in 1.5 ml of water. These samples
were applied to Sephadex G-200 columns, 42 x 3.5 cm,
equilibrated and eluted at room temperature with
10 m sodium phosphate buffer (pH 7.4). Two-ml
fractions were collected at a rate of 1 mI/mm. Trans-
ferangiotensin activity was assayed in increasing vol-
umes up to 0.4 ml aliquots from alternate fractions.
Angiotensin binding activity in plasma was tested as
already described, eluting with 10 m phosphate in
2-ml fractions. 3. Electrophoretic mobility ofangiotensin
binders. Two radioactive peaks from Sephadex G-200
column fractionation of incubation mixtures contain-
ing radioactive angiotensin II and hypertensive plasma
were pooled and lyophilized. The residues were dis-
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solved in I ml of water and 70 il samples were spotted
on cellulose acetate strips. Control strips received 35 tl
of normal serum, or labeled angiotensin II alone.
Electrophoresis was carried out at 200 v for three
hours at 4°C, in 0.083 of barbital buffer (pH 8.4).
When electrophoresis was finished, each strip was cut
into 0.5-cm pieces, and its radioactivity was counted.
Alternate cellulose acetate strips were stained with
Ponceau red and scanned at 520 m, followed by the
counting of radioactivity.
g. Identification of the radioactivity bound by
"transferangiotensin". The first peak of radioactivity
obtained from Sephadex G-200 columns developed
as described above under "Fractionation of plasma
angiotensin binders" and was tested with hypertensive
plasma as a binder. An aliquot of 15 x lOb cpm of
'251-angiotensin II bound by transferangiotensin was
spotted on four cellulose acetate strips, and electro-
phoresis was carried out as already described. The
125J peak released from the hypertensive plasma was
eluted with 4 ml of water and lyophilized. The residue
was dissolved in I ml of water and identified by per-
forming two tests: a) An aliquot of 0.4 ml plus 15 g
of unlabeled carrier angiotensin II was spotted on ion
exchange paper and was developed by chromatog-
raphy, as described herein. Unlabeled angiotensin II
was stained with ninhydrin [19] and radioactivity
determined by counting 1-cm strips. b) Another
aliquot (0.5 ml) was used as tracer angiotensin II in an
antibody-binding test [8]. The separation of the free
angiotensin II from antibody-bound angiotensin II
was performed with 1 ml of 1 % activatedcharcoal and
0.l% Dextran in 5 m phosphate buffer (pH 7.4).
Results
Each result was repeated at least three times, except
for the chromatographic analysis of plasma from
individual subjects, which was performed only once.
Activity of "transferangiotensin". "Transferangio-
tensin" activity in 14 patients with essential hyper-
tension ranged from 430 to 2,800 U/mi (Tables 2 and
3). Pooled plasma from patients with essential hyper-
tension had 1,010 U/ml (13 subjects). The level of
"transferangiotensin" activity in pooled plasma from
two patients with renal-vascular or renal parenchymal
disease was 670 and 490 U/ml, respectively. "Trans-
ferangiotensin" appears to be present in normal
plasma, but at lower levels of activity, from 105 to
410 U/ml (Table 1). Pooled plasma from six normal
subjects had an activity of 360 U/mi.
No "transferangiotensin" activity was detected in
extracts of rabbit liver homogenates.
Binding of angiotensin II. Angiotensin II binds to
arterial wall (Fig. I). Unlabeled angiotensin II corn-
Table 1. "Transferangiotensin" activity
in control plasmaa
Subject
No.
Transfer angiotensin
activity
U/mi
1 410
2 360
3 345
4 290
5 216
6 105
a Each value is the mean of three deter-
minations.
Table 2. Clinical data
Patient
No.
Duration Age Blood Creatinine
of disease yr pressure clearance
yr mmHg, ml/min/
systoiic/ 1.73 m2
diastolic
Optic
fundus
grade
Essential hypertension
7
8
9
10
11
12
13
14
15
16
17
18
19
20
5 39 160/100 1064 45 170/110 125
9 54 180/110 102
3 41 170/100 117
6 47 190/110 131
5 46 190/120 99
6 48 170/110 110
7 50 170/100 114
4 47 190/120 132
6 56 200/130 116
8 45 160/100 129
6 45 180/120 101
7 48 170/110 134
4 47 190/120 116
II
II
Il-Ill
II
lI-Ill
11-Ill
II
II
11-111
lI-Ill
II
II
II
11
Renal vascular hypertension
21
22
1 28 240/140 96
1.5 23 210/150 103
III
III
Renal parenchymal disease
23
24
25
9 35 190/130 51
8 29 180/120 26
6 32 190/120 62
III-IV
III
III-IV
petes with 125j.. angiotensin II for this binding, but
angiotensin I does not. Fifty g of protein from
arterial wall extract binds an average of l3% of
radioactive angiotensin II (22 experiments), with a
range from 10 to 42%. There was no correlation be-
tween feeding or housing conditions of the animals
and binding efficiency.
Plasma, itself, bound a mean of 8% of the 125J..
angiotensin II added, ranging from 7 to 12%. Com-
petition with labeled angiotensin II by unlabeled poly-
peptide was found (Fig. 1).
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Table 3. Analytical dataa
Patient Renin "Transfer Urinary Urinary Urinary Urinary
No. activity
ng/mi/hr of
angiotensin I
angiotensin" aldosterone V.M.A.
U/mi pg/24 hr mg/24 hr
17-keto-
steroids
mg/24 hr
17-hydroxy-
steroids
mg/24 hr
7 0.05
Essential hypertension
2,800 11 3.0 6.1 5.4
8 0.8 2,360 12 2.1 5.5 5.9
9 1.0 1,400 9 3.2 6.7 5.6
10 0.4 1,370 13 2.9 7.1 4.9
11 1.2 1,180 8 3.1 6.7 5.0
12 0.7 1,100 14 2.3 8.1 6.2
13 0.3 1,014 11 1.8 5.2 6.0
14 0.3 980 9 3.3 6.4 6.6
15 0.1 960 12 2.6 5.9 6.9
16 1.2 910 14 2.4 5.0 5.4
17 0.4 780 15 1.9 5.6 6,1
18 0.6 710 10 3.4 6.0 7.3
19 0.8 650 9 2.1 6.2 5.9
20 0.9 430 16 3.0 6.1 8.0
Renal vascular hypertension
21 39 790 17 3.6 7.6 5.6
22 61 510 15 3.1 7.3 8.1
Renal parenchymal disease
23 14 305 16 3.4 5.9 7.7
24 21 560 13 2.9 7.3 6.3
25 16 465 11 3.2 6.5 5.1
Each value is the mean of two determinations performed on samples collected while patients were not
receiving medication.
Physical-chemical properties. 1. Dialysis, pronase
digestion, heating and solvent extraction. "Transfer-
angiotensin" activity was partly destroyed by dialysis,
heating at 100°C, extraction with solvents and pronase
C
V
C
Fig. 1. Angiotensin II binding by plasma and arterial wail extract.
The experiment was performed as described in Methods.
Arterial wall (s), plasma (A).
digestion (Table 4). The activity that was lost by dialysis
was not restored by adding concentrated dialysate to
the incubation mixture. No residual pronase activity
was found after its reaction was stopped.
2. Effect of EDTA and ions. Increased "transfer-
angiotensin" activity (18 to 36%) was achieved by
adding EDTA to the incubation mixtures. Calcium
also enhanced "transferangiotensin" activity (24 to
43%). An effect of sodium or potassium salts was not
observed.
3. Optimum pH. The optimum pH for "transfer-
angiotensin" activity was 7.5, but a second optimum
was also noticeable (Fig. 2).
Characterization. 1. Fractionation of plasma angio-
tensin binders. Elution profiles of plasma binders and
labeled angiotensin II from Sephadex G-25 columns
showed two peaks of radioactivity. The first peak
migrated with the void volume, while the second
corresponded to free angiotensin II. No difference in
the peak positions was found when arterial wall
extract was added.
Elution profiles from Sephadex G-200 columns
showed significant differences, depending on the con-
tents of the incubation mixtures. When hypertensive
plasma and arterial wall extract were present, three
.05 .1
.l5sg
Angiotensin II
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peaks of radioactivity were found (Fig. 3). The most
prominent peak corresponded to the void volume.
The second had an approximate mol wt of 50,000,
while the third migrated with free angiotensin II.
When plasma was omitted from the incubation mix-
ture, only a small peak of radioactivity appeared in
the void volume position. The profile of the plasma
alone was similar to that of plasma plus arterial wall
extract, but the void volume peak was smaller.
When Sepharose 6-B was used, three peaks of radio-
activity appeared. The major peak migrated with the
void volume, while the middle peak had an approxi-
mate mol wt of 700,000 and the smallest migrated with
the combined 50,000 mol wt and free angiotensin II
position. Chromatography on Sepharose 6-B of an
incubation mixture containing arterial wall extract
alone showed three peaks of radioactivity. The first
peak migrated with the void volume, the second had a
higher exclusion volume and the third migrated with
the combined 50,000 mol wt and free angiotensin TI
position (Fig. 4).
Bound radioactivity was diminished 80% when the
incubation period was omitted, but no major change
in chromatographic profile was detected.
A similar profile was found when hypertensive
plasma was replaced by normal plasma, although the
amount of angiotensin II bound was much lower.
In brief, incubation of radioactive plasma resulted in
the appearance of more radioactivity in lower mol wt
fractions than when it was incubated with arterial wall
extract alone. There was evidence for the disappear-
ance of the second peak of the arterial extract on
Plasma
and /\
receptor
Plasma
reor/[alone
/ Receptor
H
10 30 50 70 90 100
Effluent, ml
5 6 7 8 9 pH
Fig. 2. Optimum pH. Hypertensive plasma was incubated with
radioactive angiotensin, arterial wall extract, and 10 zmoles of
Tris-HCI at different pH, as described in Methods.
Fig. 3. Typical binding profiles on Sephadex G-200 columns.
Incubation, equilibration and elution were carried out as
described in Methods. The elution profile of 1251-angiotensin II
incubated with plasma plus the arterial wall extract (•), with
plasma alone (0) and with arterial wall extract alone (U) are
shown.
Table 4. Physical chemical properties of plasma angiotensin-
binders°
Specimen "Transfer-
angiotensin"
Experimental
range
activity
Original plasma 100 100
After dialysis 32.3 — 15,3—41
Dialysis plus 0.2 ml of
dialysate 25.5 —11—48
Pronase digestion 64.5 12—71
Heating 1000 x 5 mm 62.6 2—63
Residue (0.2 ml) from
ether extraction 8.4 0.3—13
Essential hypertensive pooled plasma was divided into four
1-mi aliquots. The first aliquot was dialyzed as described in
Methods, the dialysate evaporated to dryness and the residue
dissolved in 0.5 ml. Assays of transferangiotensin activity were
run before and after dialysis and after the retentate was com-
bined with increasing amounts of the concentrated dialysate. The
second aliquot was digested with Pronase as described in
Methods. The third aliquot was extracted with ether and the
residue dissolved in 1 ml of buffer. The fourth aliquot was heated
to 100°C. Assays of transferangiotensin activity were performed
before and after each procedure, and the results expressed as
percentages of the starting activity.
2000
I 500
bOO
500
C
0
C
C
0
00
=
200
50
25
2
0,5
0
x
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Fig. 4. Typical angiotensin I! binding profiles on Sepharose 6-B
columns. The experimental procedure was performed as des-
cribed in Methods. The elution profile of '251-angiotensin II
when incubated with plasma plus arterial wall extract () is
compared with that from angiotensin plus arterial wall extract() alone.
Sepharose 6-B chromatography, when plasma was
added to the incubation mixture (Fig. 4).
2. Characterization of" transferangiotensin" activity.
Transferangiotensin activity elutes from Sepharose
6-B at a position corresponding to 700,000 mol wt. No
transferangiotensin activity was found in the position
of the 50,000 mol wt and smaller component (Fig. 5).
Between 25 and 46% of the transferangiotensin acti-
vity applied to the column was lost.
3. Electrophoretic localization. A concentrate of the
700,000 mol wt component eluted from Sepharose
6-B migrated in advance of albumin on electro-
x
Receptor
alone 900
Plasma
and
x 30 C
50 70
Effluent, ml
-t- 2 4 6 8 10 12 14 16
cm
Fig. 6. Electrophoretic localization. The heavy (•) and light (A
plasma angiotensin II binders were separated by electrophoresis,
and radioactivity migration compared with that of '251-angio-
tensin 11(0) and normal serum (—) stained with Ponceau red.
phoresis. The 50,000 mol wt component migrated with
albumin (Fig. 6).
4. Identification of the compounds bound by transfer-
angiotensin. The radioactive compound bound by the
700,000 mol wt component had an electrophoretic
migration corresponding to free angiotensin II. It
co-chromatographed with angiotensin II, and it was
displaced from anti-angiotensin II antibody by un-
labeled angiotensin II.
Discussion
The data presented in this report relate to two
phenomena: the binding of angiotensin II by human
plasma macromolecules, and the ability of one of these
binders to enhance the binding of angiotensin by
macromolecules in an extract of rabbit aorta. The
TableS. Comparative binding activity of sepharose 6-B fractionsa
20 60 100 140 180 220 260 300 340 380
Effluent, ml
Source Radioactivity, %
Plasma plus Arterial wall
arterial extract
wall extract
First peak 0.5 0.2
Second peak 0 0.4
Third peak 1.6 0
Fourth peak 97.9 99.4
Fig. 5. Identification of "transferangiotensin" activity. Experi-
mental conditions were performed as described in Methods. The
plasma component possessing transferangiotensin activity
(0) is compared with angiotensin binding activity (•).
0 Equilibration, elution and sampling were performed as des-
cribed in Methods. The total recovered 1251 (in counts per
minute, cpm) is designated 100. The percentage of cpm in the
different peaks of the incubate containing plasma plus arterial
wall extract is compared to that of the arterial wall extract alone.
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plasma binders have apparent mol wts of 50,000 and
700,000. It was the heavier one that served to increase
binding by arterial wall extracts.
The heavy factor which potentiates binding by the
arterial wall extract is thermolabile, and it is probably
protein in nature. It also migrates in advance of albu-
min during electrophoresis. We propose the name
"transferangiotensin" in order to suggest a mech-
anism of action which involves the transfer of angio-
tensin from solution in plasma to receptors in target
tissue. Transferangiotensin may also interact with a
component(s) of the arterial wall, since there was
disappearance of one binding peak in arterial wall
extract when plasma was added.
The apparent discrepancy between the effects of
calcium and the EDTA may indicate the need of
calcium ions and the simultaneous presence in the
assay system of a metal that inhibits the activity of
transferangiotensin. The loss of transferangiotensin
activity after dialysis, followed by failure to recover
the loss by addition of dialysate, can be interpreted as
the irreversible loss of a cofactor. There was less loss of
angiotensin activity after gel filtration than after
dialysis.
The differences in results of heating and pronase
digestion may perhaps be explained by the protection
afforded by concentrated protein solutions. Appar-
ently, loss of activity by the digestion of angiotensin
cannot be implicated because the enzymatic reaction
was stopped and no residual pronase activity was
found.
Angiotensin II bound by transferangiotensin does
not seem to be transformed, because the released
product chromatographs and competes for antibody
with angiotensin II.
Lack of transferangiotensin activity in a binding
fraction with a mol wt of 50,000 that migrates with
albumin could be interpreted either as binding by
albumin itself, or by a subunit from the heavier
component.
The data do not bear on the kinetics of transfer-
angiotensin activity, its specificity for other molecules
such as norepinephrine or the mechanism of its inter-
action with a receptor. However, its increased activity
in plasma from patients with benign essential hyper-
tension does suggest that it may play a possible role in
the pathogenesis of hypertension. The wide range
of transferangiotensin activity (430 to 2,800 U/ml)
among patients with essential hypertension also im-
plies that the pathogenesis of this disease may well be
multifaceted.
The relationship of transferangiotensin (or the
50,000 mol wt plasma binder as well) to those described
by others is unknown [4—7], as is the relationship of
our arterial extract to the "receptors" that have been
prepared from rabbit aorta by Devynck et a! [20].
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